Since MYD88-L265P mutation status and mRNA expression levels are readily determined in a clinical setting it will be important to extend these observations in future, and evaluate whether this combination can be used to prospectively identify a subset of good risk ABC-DLBCL cases. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.